Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;47(6):1315-1321.
doi: 10.1007/s40618-023-02237-7. Epub 2023 Nov 21.

Diabetes technology and sexual health: which role?

V Zamponi  1 , J Haxhi  1 , G Pugliese  1 , A Faggiano  1 , R Mazzilli  2
Affiliations
Review

Diabetes technology and sexual health: which role?

V Zamponi et al. J Endocrinol Invest. 2024 Jun.

Abstract

Purpose: The aim of this review is to evaluate the effects of new technology used in the management of diabetes mellitus (DM), including the use of continuous glucose monitoring (CGM) and the administration of insulin through continuous subcutaneous insulin infusion (CSII), on male and female sexual function.

Methods: This narrative review was performed for all available prospective, retrospective and review articles, published up to June 2023 in PubMed. Data were extracted from the text and from the tables of the manuscript.

Results: Sexual dysfunctions are an underestimated comorbidity of DM in both male and female. Although erectile dysfunction (ED) is recognized by the guidelines as a complication of DM, female sexual dysfunction (FSD) is poorly investigated in clinical setting. In addition to the complications of DM, the different types of therapies can also influence male and female sexual response. Furthermore, insulin therapy can be administered through multiple-daily injections (MDI) or a CSII. The new technologies in the field of DM allow better glycemic control which results in a reduction in the occurrence or aggravation of complications of DM. Despite this evidence, few data are available on the impact of new technologies on sexual dysfunctions.

Conclusions: The use of DM technology might affect sexual function due to the risk of a worse body image, as well as discomfort related to CSII disconnection during sexual activity. However, the use is related to an improved metabolic control, which, in the long-term associates to a reduction in all diabetes complications, including sexual function.

Keywords: Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Diabetes; Erectile dysfunction; Female sexual dysfunction; Technology.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Pros and cons of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) use on male and female sexual function
See this image and copyright information in PMC

References

    1. American Diabetes Association Diagnosis and classification of diabetes mellitus (2013) Diabetes Care. 2013;36(Suppl 1):S67–S74. doi: 10.2337/dc13-S067. - DOI - PMC - PubMed
    1. Defeudis G, Mazzilli R, Tenuta M, Rossini G, Zamponi V, Olana S, Faggiano A, Pozzilli P, Isidori AM, Gianfrilli D. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022;38(2):e3494. doi: 10.1002/dmrr.3494. - DOI - PMC - PubMed
    1. Zamponi V, Mazzilli R, Bitterman O, Olana S, Iorio C, Festa C, Giuliani C, Mazzilli F, Napoli A. Association between type 1 diabetes and female sexual dysfunction. BMC Womens Health. 2020;20(1):73. doi: 10.1186/s12905-020-00939-1. - DOI - PMC - PubMed
    1. Daly A, Hovorka R. Technology in the management of type 2 diabetes: present status and future prospects. Diabetes Obes Metab. 2021;23(8):1722–1732. doi: 10.1111/dom.14418. - DOI - PMC - PubMed
    1. Corona G, Isidori AM, Aversa A, Bonomi M, Ferlin A, Foresta C, La Vignera S, Maggi M, Pivonello R, Vignozzi L, Lombardo F. Male and female sexual dysfunction in diabetic subjects: focus on new antihyperglycemic drugs. Rev Endocr Metab Disord. 2020;21(1):57–65. doi: 10.1007/s11154-019-09535-7. - DOI - PubMed